A Double-blind, Randomized, Controlled Dose Escalation Trial of Autologous Mesenchymal Stromal Cells in Living Donor Kidney Transplant Recipients

Investigator: Ahmed Gaber, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT03478215

Phone:

Protocol Number: Pro00012858

Description

Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients receive induction therapy and immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. This research study will evaluate the safety and activity of mesenchymal stromal stem cells (MSCs) infusion compared to saline-only infusion in reducing the immune suppression necessary to achieve optimal renal function in renal transplant recipients. All participants will receive routine care: basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials